The Tel Aviv University study published in Inflammation and Regeneration demonstrates that intravenous administration of a glutamate-clearing agent within eight hours of spinal cord injury in mice reduces secondary excitotoxicity, limits glial scarring, and yields up to 80 percent motor recovery versus 30 percent in controls. This is an animal-model experiment validated by an independent CRO, not a randomized human trial; sample sizes remain modest and species-specific pharmacokinetics limit direct translation. Prior human efforts, such as the Riluzole trials in acute SCI (e.g., the 2016–2022 multicenter studies), targeted similar glutamate pathways yet failed to meet primary endpoints partly because oral dosing delayed therapeutic levels. The new approach bypasses the blood-brain barrier problem by systemic clearance, a mechanistic insight missed in earlier coverage that focused only on functional scores. Connections to blast-related traumatic brain injury, highlighted by the researchers after October 7 events, suggest broader utility in military and civilian polytrauma where the therapeutic window aligns with first-responder timelines. Limitations include unknown long-term safety, potential off-target effects on peripheral glutamate signaling, and absence of data on chronic pain or autonomic outcomes that dominate patient-reported disability. If replicated in larger gyrencephalic models and early-phase human safety studies, this could shift trauma protocols from supportive care to disease-modifying intervention, though regulatory approval will require rigorous Phase II/III evidence currently lacking.